WALTHAM, Mass., Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:Event: TD Cowen 45th Annual Healthcare ConferenceFormat: Fireside chat and 1x1 meetingsDate/Tim ...